Abstract 1034P
Background
Camrelizumab (Camre) is a humanized PD-1 monoclonal antibody. Escort study reported Camre as monotherapy for previously treated advanced ESCC patients (pts) showed superior efficacy compared to chemotherapy. Camre combined with chemotherapy or apatinib in the treatment of local advanced or metastatic ESCC might be a feasible approach to provide antitumor activity superior to either agent alone. However, the available data about the combination strategy is limited.
Methods
This is a multi-center, prospective cohort study of local advanced or metastatic ESCC at the Second Affiliated Hospital of Suzhou University and Kunshan First People's Hospital, Suzhou, China. No other restrictive inclusion criteria were applied. All the data were captured with electronic uniform database templates to ensure consistent data collection. The primary endpoints is objective response rate (ORR),the secondary endpoints are adverse events (AE), disease control rate (DCR), and progression-free survival (PFS).
Results
A total of 15 pts were enrolled. Median age was 63, male 66.7% and 53.3% with metastatic disease. 26.7% were treated as first-line therapy, 46.7 as second-line and 26.7% as third-line and above-line treatment. Treatment regimens included camrelizumab monotherapy 13.3%(2/15), combination chemotherapy 26.7%(4/15), combination apatinib 60%(9/15). 15 pts were accessible for efficacy analysis. The ORR and DCR were 26.7% (4/15) and 73.3%(11/15), respectively, including one complete response combination apatinib after radiation treatment. This was an early stage of data analysis, the PFS has not yet reached. Toxicity profile was mild with mainly grade 1 adverse events.The most common AEs were reactive cutaneous capillary hyperplasia (RCCEP) (4/15), fatigue (4/15) and nausea (2/15). No treatment-related deaths occurred.
Conclusions
This Real-world research provides preliminary evidence for camrelizumab in treatment of patients with local advanced or metastatic ESCC. The combination regimen warrants further exploration in a prospective clinical trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.